Hypersensitivity to the active substance or to any of the excipients used in manufacture of Drug Product.
Co-administration with CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide or quinidine since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes.
Co-administration with rifampicin, carbamazepine and phenobarbital since these medicinal products are likely to decrease plasma voriconazole concentrations significantly.
Coadministration with high dose efavirenz (400 mg and above once daily) because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at this dose.
Co-administration with high dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose.
Co-administration with ergot alkaloids (ergotamine, dihydroergotamine), which are CYP3A4 substrates, since increased plasma concentrations of these medicinal products can lead to ergotism.
Co-administration with sirolimus, since voriconazole is likely to increase plasma concentrations of sirolimus significantly.
Coadministration with St John's Wort.
Hepatic impairment: in mild to moderate hepatic cirrhosis use usual initial dose then halve subsequent doses; no information available for severe hepatic cirrhosis - manufacturer advises use only if potential benefit outweighs risk.
Renal impairment: intravenous vehicle may accumulate if eGFR less than 50 ml/minute/1.73 m2 - use intravenous infusion only if potential benefit outweighs risk, and monitor renal function; alternatively, use tablets or oral suspension (no dose adjustment required).